Search

Search Constraints

You searched for: Author/Creator Roecker, Anthony J.

Search Results

1. Association of respiratory failure with inhibition of NaV1.6 in the phrenic nerve. Issue 1 (31st December 2022)

3. Cover Picture: Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia (ChemMedChem 2/2014). Issue 2 (February 2014)

4. Discovery of 5′′‐Chloro‐N‐[(5, 6‐dimethoxypyridin‐2‐yl)methyl]‐2, 2′:5′, 3′′‐terpyridine‐3′‐carboxamide (MK‐1064): A Selective Orexin 2 Receptor Antagonist (2‐SORA) for the Treatment of Insomnia. Issue 2 (27th December 2013)

5. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Issue 21 (1st November 2015)

6. Discovery of diazepane amide DORAs and 2-SORAs enabled by exploration of isosteric quinazoline replacements. Issue 21 (1st November 2015)

7. Discovery of selective, orally bioavailable, N-linked arylsulfonamide Nav1.7 inhibitors with pain efficacy in mice. Issue 10 (15th May 2017)

8. Investigation of orexin-2 selective receptor antagonists: Structural modifications resulting in dual orexin receptor antagonists. Issue 6 (15th March 2017)

9. The dual orexin receptor antagonist, DORA‐22, lowers histamine levels in the lateral hypothalamus and prefrontal cortex without lowering hippocampal acetylcholine. Issue 2 (1st June 2017)